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It is increasingly evident that organophos-
phate insecticides affect mammalian brain
development through a variety of mecha-
nisms. In animal studies or in vitro models of
neurodevelopment, chlorpyrifos (CPF;
O,O-diethyl O-[3,5,6-trichloro-2-pyridyl
ester]phosphorothioate), the most widely
applied insecticide, has direct and indirect
effects on neural cell replication and differen-
tiation, resulting in immediate and delayed-
onset changes in synaptogenesis (Barone et al.
2000; Casida and Quistad 2004; Gupta
2004; Pope 1999; Slotkin 1999, 2004;
Slotkin et al. 2001), neurotransmitter release
(Aldridge et al. 2005; Bloomquist et al. 2002;
Dam et al. 1999a; Liu and Pope 1998),
expression of neurotransmitter receptors
(Chaudhuri et al. 1993; Dam et al. 1999b;
Huff and Abou-Donia 1995; Katz et al.
1997; Richardson and Chambers 2005), and
intracellular signaling (Huff et al. 2001;
Meyer et al. 2004a; Schuh et al. 2002), over
and above the consequences of cholinesterase
inhibition. Because of this diversity, the criti-
cal period for the effects of CPF exposure
depends highly upon the maturational stage
of each brain region as well as the specific
neurotransmitter, producing a wide window
of vulnerability with shifting regional and cel-
lular targets as development proceeds (Pope
1999; Rice and Barone 2000; Slotkin 2004).
Indeed, CPF can even exert simultaneous,
opposite effects on axonal and dendritic
growth (Howard et al. 2005).
The disparate nature of CPF effects on
brain development, combined with potential
impact on the maternal–fetal unit or general
aspects of fetal or neonatal growth and
development, renders it especially difﬁcult to
identify speciﬁc underlying mechanisms from
in vivo studies or to discern why specific
developmental stages or neurotransmitter sys-
tems might be especially targeted by CPF.
Accordingly, recent attention has focused on
in vitro models, including neuronotypic and
gliotypic cells as well as primary cultures of
mixed neurons and glia (Garcia et al. 2001;
Howard et al. 2005; Olivier et al. 2001;
Sachana et al. 2001; Schuh et al. 2002; Song
et al. 1998). PC12, a transformed neurono-
typic cell line, provides one of the most useful
model systems for evaluations of develop-
mental neurotoxicants (Crumpton et al. 2000;
Das and Barone 1999; Fujita et al. 1989;
Madhok and Sharp 1992; Qiao et al. 2001,
2005; Song et al. 1998; Teng and Greene
1994). As immature neuronal precursors,
these cell maintain mitotic activity in culture
(whereas primary neurons lose that ability),
enabling assessments of adverse effects on
DNA synthesis and cell replication (Qiao
et al. 2001, 2003; Song et al. 1998). Upon
addition of nerve growth factor (NGF), PC12
cells begin to differentiate and develop axonal
projections and electrical excitability (Das and
Barone 1999; Fujita et al. 1989; Teng and
Greene 1994), whereas mitotic activity gradu-
ally declines over a period of about 10 days
(Qiao et al. 2001, 2003; Song et al. 1998).
Critical for their use in modeling the develop-
mental neurotoxicity of CPF, PC12 cells dif-
ferentiate specifically into two phenotypes,
cholinergic and catecholaminergic (Fujita
et al. 1989; Teng and Greene 1994). Studies
of CPF effects on brain development in vivo
indicate high susceptibility of these two trans-
mitter systems, but with disparate patterns.
Cholinergic systems are among the most sensi-
tive, showing both immediate and lasting
damage when CPF exposure occurs during
periods of rapid cell replication and differentia-
tion (Barone et al. 2000; Pope 1999; Rice and
Barone 2000; Slotkin 2004; Vidair 2004); in
contrast, the initial effects on catecholamine
systems appear to be promotional (Dam et al.
1999b), although long-term deﬁcits in func-
tion eventually appear (Aldridge et al. 2005;
Slotkin et al. 2002) as part of the pattern of
late-developing, widespread disruption of
synaptic connectivity in multiple neuro-
transmitter systems (Barone et al. 2000; Pope
1999; Rice and Barone 2000; Slotkin 2004;
Vidair 2004).
In this study we used the PC12 model to
address several key aspects of the develop-
mental neurotoxicity of CPF. Does CPF have
disparate effects on neuronal development
during phases of cell replication as opposed to
differentiation? Does CPF alter the ability of
developing neurons to express a specific
neurotransmitter phenotype, and if so, at what
stage of maturation does this occur? Do these
changes occur at CPF concentrations below
those necessary for effects on viability? To
answer these questions, we evaluated PC12
cells in the undifferentiated state (CPF with-
out NGF), at the initiation of differentiation
(inclusion of CPF simultaneously with the
addition of NGF), and at mid-differentiation
(CPF added after several days of NGF pre-
treatment), evaluating cell viability, DNA
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The organophosphate insecticide chlorpyrifos (CPF) adversely affects mammalian brain develop-
ment through multiple mechanisms. To determine if CPF directly affects neuronal cell replication
and phenotypic fate, and to identify the vulnerable stages of differentiation, we exposed PC12 cells,
a model for mammalian neurodevelopment, to CPF concentrations spanning the threshold for
cholinesterase inhibition (5–50 µM) and conducted evaluations during mitosis and in early and
mid-differentiation. In undifferentiated cells, exposure to 5 µM CPF for 1–3 days reduced DNA
synthesis signiﬁcantly without eliciting cytotoxicity. At the same time, CPF increased the expres-
sion of tyrosine hydroxylase (TH), the enzymatic marker for the catecholamine phenotype, without
affecting choline acetyltransferase (ChAT), the corresponding marker for the cholinergic pheno-
type. Upon exposure to nerve growth factor (NGF), PC12 cells developed neuritic projections in
association with vastly increased TH and ChAT expression accompanying differentiation into the
two phenotypes. CPF exposure begun at the start of differentiation signiﬁcantly reduced ChAT but
not TH activity. In contrast, when CPF was added in mid-differentiation (4 days of NGF pre-
treatment), ChAT was unaffected and TH was increased slightly. Thus, CPF exerts stage-speciﬁc
effects, reducing DNA synthesis in the undifferentiated state, impairing development of the cholin-
ergic phenotype at the start of differentiation, and promoting expression of the catecholaminergic
phenotype both in undifferentiated and differentiated cells. CPF administration in vivo produces
deﬁcits in the number of neurons and cholinergic function, and because we were able to reproduce
these effects in vitro, our results suggest that CPF directly inﬂuences the phenotypic fate of neuronal
precursors. Key words: acetylcholine, brain development, catecholamines, chlorpyrifos, DNA syn-
thesis, organophosphate insecticides, PC12 cells. Environ Health Perspect 114:667–672 (2006).
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enzymatic markers that characterize the
cholinergic or catecholaminergic phenotype:
choline acetyltransferase (ChAT) and tyrosine
hydroxylase (TH), respectively. Because CPF
exposure can affect the number of cells, cell
growth, or neuritic extension (Das and Barone
1999; Song et al. 1998), values were deter-
mined relative to cell number (per unit DNA)
as well as to cell protein. Assessments were
conducted at 5–50 µM CPF (1.7–17 µg/mL),
concentrations bracketing the threshold for
cholinesterase inhibition (Das and Barone
1999) and for adverse effects on cell number
(Song et al. 1998). Finally, to determine
whether nonorganophosphate cholinesterase
inhibitors could elicit similar effects, we evalu-
ated the effects of physostigmine compared
with CPF.
Materials and Methods
PC12 cell culture and treatments. As described
previously (Crumpton et al. 2000; Qiao et al.
2003; Song et al. 1998), PC12 cells (1721-
CRL; American Type Culture Collection,
Rockville, MD) were grown in RPMI-1640
medium (Invitrogen, Carlsbad, CA) supple-
mented with 10% inactivated horse serum
(Sigma Chemical Co., St. Louis, MO), 5%
fetal bovine serum (Sigma), and 50 µg/mL
penicillin–streptomycin (Invitrogen); cells were
incubated with 7.5% CO2 at 37°C, and the
medium was changed every 2 days. Because of
the clonal instability of the PC12 cell line
(Fujita et al. 1989), the experiments were per-
formed on cells that had undergone fewer than
ﬁve passages, and studies were repeated several
times with different batches of cells. For studies
in the undifferentiated state, 3–6 × 106 cells
were seeded onto 100-mm poly-L-lysine–
coated plates, and 24 hr later the medium was
changed to include 5 or 50 µM CPF (purity,
98%; Chem Service, West Chester, PA). CPF
was dissolved in dimethyl sulfoxide (DMSO),
achieving final DMSO concentrations of
0.1–1% in the culture medium, and the corre-
sponding control samples contained equivalent
DMSO concentrations. Preliminary studies
were conducted to verify that these concentra-
tions of DMSO had no effect on the measured
parameters in PC12 cells (data not shown), in
agreement with earlier work (Qiao et al. 2001,
2003; Song et al. 1998).
For studies during differentiation, 3.5 × 106
cells were seeded; 24 hr later the medium was
changed to include 50 ng/mL NGF (Sigma),
and over the ensuing week, each culture was
examined under a microscope to verify the
outgrowth of neurites. CPF or physostigmine
(Sigma) was added either simultaneously with
the addition of NGF or after a 4-day NGF
pretreatment.
DNA synthesis. To initiate the measure-
ment of DNA synthesis, the medium was
changed to include 1 µCi/mL [3H]thymidine
(speciﬁc activity, 2 Ci/mmol; GE Healthcare,
Piscataway, NJ) along with the continued
inclusion of CPF or DMSO vehicle. After
1 hr, the medium was aspirated and cells were
harvested in 3.5 mL ice-cold water. Duplicate
aliquots of each sample were treated with 10%
trichloroacetic acid and sedimented at
1,000 × g for 15 min to precipitate macro-
molecules. The resulting pellet was washed
once with additional trichloroacetic acid and
then with 75% ethanol. The final pellet was
hydrolyzed with 1 M KOH overnight at 37°C
and neutralized with 6 M HCl, and the DNA
was precipitated with ice-cold 5% trichloro-
acetic acid and resedimented. The supernatant
solution, comprising solubilized RNA and
protein, was discarded. The DNA-containing
pellet was hydrolyzed in 5% trichloroacetic
acid for 15 min at 90°C and resedimented,
and an aliquot of the supernatant solution was
counted for radiolabel. Another aliquot was
assayed for DNA spectrophotometrically by
absorbance at 260 nm. Previous work has
demonstrated quantitative recovery of DNA
by these techniques (Bell et al. 1986; Slotkin
et al. 1984). Incorporation values were cor-
rected to the amount of DNA present in each
culture to provide an index of macromolecule
synthesis per cell.
Enzyme activities. Cells were harvested as
described above and were disrupted by
homogenization in a ground-glass homogenizer
ﬁtted with a ground-glass pestle, using a buffer
consisting of 154 mM NaCl and 10 mM
sodium-potassium phosphate (pH 7.4). An
aliquot was withdrawn for measurement of
protein (Smith et al. 1985).
ChAT assays (Lau et al. 1988) were con-
ducted with 40 µg of sample protein in 60 µL
of a buffer consisting of 60 mM sodium phos-
phate (pH 7.9), 200 mM NaCl, 20 mM
choline chloride, 17 mM MgCl2, 1 mM
EDTA, 0.2% Triton X-100, 0.12 mM
physostigmine (Sigma), and 0.6 mg/mL
bovine serum albumin (Sigma), containing a
final concentration of 50 µM [14C]acetyl-
coenzyme A (speciﬁc activity of 44 mCi/mmol,
diluted with unlabeled compound to
6.7 mCi/mmol; PerkinElmer Life Sciences,
Boston, MA). Blanks contained homogeniza-
tion buffer instead of the tissue homogenate.
Samples were preincubated for 15 min on ice,
transferred to a 37°C water bath for 30 min,
and the reaction terminated by placing the
samples on ice. Labeled acetylcholine was
then extracted and counted in a liquid scintil-
lation counter, and the activity was deter-
mined relative to DNA or protein.
TH activity was measured using [14C]tyro-
sine as a substrate and trapping the evolved
14CO2 after coupled decarboxylation with
DOPA decarboxylase (Lau et al. 1988;
Waymire et al. 1971). Homogenates were
sedimented at 26,000 × g for 10 min to
remove storage vesicles containing cate-
cholamines, which interfere with TH activity,
and assays were conducted with 100 µL
aliquots of the supernatant solution in a total
volume of 550 µL. Each assay contained ﬁnal
concentrations of 910 µM FeSO4, 55 µM
unlabeled L-tyrosine (Sigma), 9.1 µM pyridoxal
phosphate (Sigma), 36 µM β-mercaptoethanol,
and 180 µM 2-amino-6,7-dimethyl-4-hydroxy-
5,6,7,8-tetrahydropteridine HCl (Sigma), all in
a buffer of 180 mM sodium acetate and
1.8 mM sodium phosphate (pH 6.1). Each
assay contained 0.5 µCi of generally labeled
[14C]tyrosine (speciﬁc activity, 438 mCi/mmol;
Sigma) as substrate, and blanks contained
buffer in place of the homogenate.
Viability. Cell viability was assessed in
separate cultures. The medium was changed
to include trypan blue (Sigma; 1 vol per
2.5 vol of medium), and cells were examined
for staining under 400× magnification,
counting an average of 100 cells per field in
four different ﬁelds per culture.
Data analysis. Data are presented as means
and SEs. For each type of study, treatment dif-
ferences were first evaluated with a global
analysis of variance (ANOVA; data log-trans-
formed whenever variance was heterogeneous)
incorporating all variables: cell batch number,
CPF concentration, time, and the presence or
absence of NGF. Based on the interactions of
CPF with the other factors, data were then
subdivided for lower-order tests, followed by
Fisher’s protected least signiﬁcant difference to
establish individual values that differed from
the corresponding controls. Significance was
assumed at the level of p < 0.05 for main
effects; however, for interactions at p < 0.1, we
also examined whether lower-order main
effects were detectable after subdivision of the
interactive variables (Snedecor and Cochran
1967). In the initial test, the results did not
vary among the different batches of cells, so
results across the different batches were com-
bined for presentation, and the indicated
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Figure 1. Effects of CPF treatment on DNA synthe-
sis in undifferentiated PC12 cells. Data are means
and SEs. ANOVA across both time points appears
at the top of the panel.
*Signiﬁcantly different from the corresponding control.
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ANOVA: Treatment, p < 0.0001 (n = 6)number of samples in each experiment reﬂects
the total number of cultures.
Results
Undifferentiated cells. Earlier work demon-
strated that CPF causes immediate decrements
in DNA synthesis in undifferentiated PC12
cells (Qiao et al. 2001; Song et al. 1998).
Because the present study evaluated longer-
term effects, we measured [3H]thymidine
incorporation after CPF exposures of 1 and
3 days (Figure 1). At 5 µM, the threshold con-
centration for immediate inhibition of DNA
synthesis (Song et al. 1998), CPF elicited a sig-
niﬁcant reduction in [3H]thymidine incorpora-
tion that was sustained through the 3 days of
treatment. Nevertheless, the total number of
cells remained within normal bounds, and there
was no decrease in viability as assessed with try-
pan blue staining (Figure 2A); similarly, indices
of overall cell growth (protein:DNA ratio) or
cell surface area (membrane protein/total pro-
tein) were not signiﬁcantly affected (data not
shown). Across both measurements (per
microgram DNA, per microgram protein;
Figure 2, B and C taken together) of the
neurotransmitter-related enzymes, evaluation
of ChAT and TH indicated a signiﬁcant CPF
× enzyme interaction (p < 0.02), reﬂecting a
preferential increase in TH (p < 0.05) without
an effect on ChAT. For the index of activity
per cell (Figure 2B), there was no signiﬁcant
effect on either enzyme, whereas activity per
unit protein showed a small but significant
increase in TH (Figure 2C).
CPF exposure commencing at differentia-
tion. When 5 µM CPF was added simultane-
ously with NGF, there was no change in total
DNA at the end of a 1-week exposure, but
raising the concentration to 50 µM produced a
signiﬁcant shortfall (Figure 3A); earlier work
showed only a small (3%) decrease in viability
after even longer exposures to much higher
CPF concentrations (Song et al. 1998). By
itself, NGF-induced differentiation elicited
massive increments in ChAT and TH activity
relative to undifferentiated cells (compare
scales in Figure 2B,C vs. Figure 3B,C). In stark
contrast to the lack of effect of CPF on ChAT
in undifferentiated cells, the addition of CPF
at the start of differentiation resulted in a pro-
found deficit in ChAT, discernible at either
5 or 50 µM CPF for activity expressed either
per microgram DNA (Figure 3B) or per
microgram protein (Figure 3C). TH showed
small increments at either concentration that
did not achieve statistical signiﬁcance but that
were also not distinguishable from the signiﬁ-
cant increments found in undifferentiated cells
(no CPF × ±NGF interaction).
CPF added after the initiation of differen-
tiation. When cells underwent 4 days of 
NGF-induced differentiation before the addi-
tion of CPF, quite different results were
obtained for effects on ChAT and TH, but not
for general indices of cellular development. By
1 week after the initiation of differentiation
(7 days after the start of NGF, exposure to
5 µM CPF for the final 3 days), there was a
small decrement in DNA content at the mar-
gin of statistical signiﬁcance (p < 0.06) and no
change in viability as assessed with trypan blue
staining (Figure 4A). ChAT activity per cell
was unaffected by CPF treatment, whereas the
corresponding measure for TH showed a sig-
niﬁcant increase (Figure 4B). Activity per unit
protein showed the same trend, although for
this measure the TH effect was at the margin
of signiﬁcance (p < 0.07) (Figure 4C). The lack
of effect on ChAT was entirely separable from
the significant effect seen when CPF was
added simultaneously with NGF (p < 0.003
for CPF × treatment paradigm). However, the
increment in TH was indistinguishable from
the smaller, nonsigniﬁcant promotional effect
seen with the simultaneous NGF + CPF para-
digm, or from the significant increment in
undifferentiated cells (p < 0.01 for the main
effect of CPF, without a signiﬁcant interaction
of CPF × treatment paradigm).
Effects of physostigmine. To contrast the
effects of CPF with a nonorganophosphate
cholinesterase inhibitor, we performed parallel
studies in differentiating cells exposed to a
carbamate, physostigmine. Compared with
CPF, physostigmine elicited much greater
Neurodevelopmental effects of chlorpyrifos
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Figure 2. Effects of a 3-day CPF treatment on undifferentiated PC12 cells. NS, not signiﬁcant. (A) Cell number (DNA content) and percentage of nonviable cells
(trypan blue staining). (B) ChAT and TH activity per cell (i.e., per microgram DNA). (C) ChAT and TH activity per microgram protein. Data are means and SEs.
*Signiﬁcantly different from the corresponding control. Across both types of enzyme activity measures [per microgram DNA, per microgram protein, (B) and (C) taken together], ANOVA
also indicated a signiﬁcant treatment × measure interaction (p < 0.02) with no signiﬁcant effect on ChAT (p > 0.3) but a signiﬁcant increase in TH (p < 0.05).
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Figure 3. Effects of CPF treatment on differentiating PC12 cells; CPF was added simultaneously with NGF and differentiation was carried out for a 7-day period. (A) Cell
number (DNA content). (B) ChAT and TH activity per cell (i.e., per microgram DNA). (C) ChAT and TH activity per microgram protein. Data are means and SEs.
*Signiﬁcantly different from the corresponding control. Across both types of enzyme activity measures (per microgram DNA, per microgram protein), ANOVA also indicated a signiﬁcant
main treatment effect (p < 0.0001) and a treatment × measure interaction (p < 0.0001) with a signiﬁcant decrease in ChAT (p < 0.0001) but no signiﬁcant effect on TH (p > 0.8).
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DNAdeﬁcits in DNA but slightly smaller effects on
ChAT. At 50 µM, physostigmine evoked loss
of more than one-third of the cells (Figure 5A)
while reducing ChAT about 20% relative to
DNA (Figure 5B) or 25% relative to protein
(Figure 5C). Physostigmine had no net effect
on TH activity relative to either DNA or
protein (Figure 5B,C).
Discussion
In earlier work, CPF was shown to inhibit cell
acquisition and neurite outgrowth in PC12
cells (Das and Barone 1999; Qiao et al. 2001;
Song et al. 1998), mimicking some of the pri-
mary effects of this agent on the developing
brain in vivo (Barone et al. 2000; Pope 1999;
Rice and Barone 2000; Slotkin 2004). Results
of the present study indicate that, at the same
concentrations, CPF also has direct effects on
differentiation that determine the phenotypic
fate of developing neuronotypic cells.
Speciﬁcally, the cholinergic phenotype is vul-
nerable at the earliest stage of differentiation,
the transition from cell replication to speciali-
zation, and the CPF effects are seen in the
absence of signiﬁcant cell loss or cytotoxicity.
Indeed, the period in which ChAT was sus-
ceptible to CPF is specifically the stage in
which PC12 cells shift away from mitosis and
toward differentiation into the two pheno-
types, in association with greatly increased
levels of neurotransmitter synthetic enzymes
(Kalisch et al. 2002). As shown here, the
effects on ChAT expression display a clearly
delineated critical period, with virtually no
effect either in undifferentiated cells or in
later stages of differentiation. By way of con-
trast, the slight promotional effect on the
catecholaminergic phenotype was seen in
both undifferentiated and differentiated cells,
suggesting an entirely separate mechanism.
Importantly, the same dichotomy for the two
phenotypes is seen in the developing brain
after CPF exposure in vivo (Barone et al.
2000; Dam et al. 1999b; Pope 1999; Rice
and Barone 2000; Slotkin 2004; Vidair
2004). Indeed, similar changes may occur in
peripheral cholinergic and catecholaminergic
pathways, where CPF exposure in neonatal
rats enhances β-adrenergic effects at the
expense of muscarinic cholinergic actions
(Meyer et al. 2004b; Slotkin et al. 2005).
Our findings thus provide an underlying
mechanism for the differential effects of CPF
on the diverse neuronal cell populations con-
tained within each brain region, super-
imposed on more general aspects of cell loss
and impaired axonogenesis and synaptogene-
sis (Slotkin 1999, 2004).
The lower concentration used here, 5 µM,
lies within the range of estimated household
childhood exposure to CPF (Gurunathan
et al. 1998) and of CPF concentrations in fetal
meconium (Ostrea et al. 2002) but is below
the threshold for cholinesterase inhibition
(Das and Barone 1999); the in vivo CPF
metabolite, CPF oxon, is the active agent that
produces irreversible anticholinesterase actions
and is three orders of magnitude more potent
than CPF itself in inhibiting cholinesterase
(Das and Barone 1999). Like most neurono-
typic cells, PC12 cells lack cytochrome P450
activity, which is required for conversion to the
oxon (Mapoles et al. 1993), so inhibition is
obtained only when the concentration is raised
above the 5 µM value (Das and Barone 1999).
Given that the symptoms of organophosphate
intoxication do not emerge until cholinesterase
activity is reduced by > 70% (Clegg and van
Gemert 1999), the impact on neuronal
development of the cholinergic phenotype is
likely to be seen even with exposures that typi-
cally go unrecognized. Indeed, the adverse
effect on early differentiation into cholinergic
neurons appears to be among the most sensi-
tive effects, independent of the more general
inhibition of cell replication or axonogenesis.
At 5 µM CPF, although we found signiﬁ-
cant inhibition of DNA synthesis on undif-
ferentiated cells, there was no cumulative
deﬁcit in cell number as assessed by the DNA
content, whereas at higher concentrations,
these deficits become significant (Song et al.
Jameson et al.
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Figure 4. Effects of CPF treatment after the initiation of differentiation in cells pretreated with NGF for 4 days before the addition of CPF and with incubations con-
tinued for 3 additional days. NS, not signiﬁcant. (A) Cell number (DNA content) and percentage of nonviable cells (trypan blue staining). (B) ChAT and TH activity
per cell (i.e. per microgram DNA). (C) ChAT and TH activity per microgram protein. Data are means and SEs.
*Signiﬁcantly different from the corresponding control. Across both types of enzyme activity measures (per microgram DNA, per microgram protein), ANOVA also indicated a signiﬁcant
treatment × measure interaction (p < 0.006) with no signiﬁcant effect on ChAT (p > 0.3) but a signiﬁcant increase in TH (p < 0.04).
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Figure 5. Effects of physostigmine treatment on differentiating PC12 cells. Physostigmine was added simultaneously with NGF and differentiation was carried out
for a 7-day period. (A) Cell number (DNA content). (B) ChAT and TH activity per cell (i.e., per microgram DNA). (C) ChAT and TH activity per microgram protein.
Data are means and SEs.
*Signiﬁcantly different from the corresponding control. Across both types of enzyme activity measures (per microgram DNA, per microgram protein), ANOVA also indicated a signiﬁcant
main treatment effect (p < 0.002) and a treatment × measure interaction (p < 0.0001) with a signiﬁcant decrease in ChAT (p < 0.0001) but no signiﬁcant effect on TH (p > 0.4).
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thesis is either offset by the small, nonsigniﬁ-
cant improvement in cell viability (reduced
trypan blue staining), or alternatively, other
phases of the cell cycle are rate limiting for
replication, such that a slight slowing of DNA
synthesis has no impact on the number of
cells. Nevertheless, with the initiation of
NGF-induced differentiation, the same con-
centration had a profound impact on ChAT.
As further evidence for a complete separation
of these two effects, in the differentiating
cells, 5 µM CPF exerted its adverse effects on
the cholinergic phenotype without affecting
DNA content or cell viability; raising the con-
centration to 50 µM compromised cell acqui-
sition, but then there was an even more
profound effect on ChAT (20% deficit in
DNA, 40% deficit in ChAT:DNA), again
consistent with specificity toward expression
of the cholinergic phenotype. The targeting
of cholinergic differentiation is also distinct
from effects of CPF on axonogenesis. When
we pretreated the cells with NGF, followed by
a subsequent CPF exposure, the adverse effect
on ChAT was no longer evident; in contrast,
the same sequence enhances the ability of
CPF to inhibit neurite outgrowth (Das and
Barone 1999). Finally, the ability of CPF to
impair differentiation into the cholinergic
phenotype does not represent selective cyto-
toxicity. We saw no evidence for decreased
viability, nor did we see an equivalent increase
in the TH:DNA ratio as would have been
expected from the selective loss of cholinergic
cells and sparing of catecholaminergic cells.
Similarly, in primary neuronal/glial cultures,
CPF reduces ChAT expression without com-
parable cytotoxicity (Monnet-Tschudi et al.
2000; Zurich et al. 2004).
The results for TH, the marker for appear-
ance of the catecholaminergic phenotype, con-
firm that CPF does not simply impede cell
differentiation as a whole. Rather than show-
ing a decrease, TH activity was induced when
CPF was applied to cells either in an undiffer-
entiated state or after the onset of differentia-
tion. This suggests that CPF alters basal TH
activity through mechanisms entirely separable
from its impact on differentiation into the
cholinergic phenotype. Although our studies
do not address the molecular mechanisms
underlying the dissimilar impact on choliner-
gic and catecholaminergic phenotypes, there
are a number of likely candidates. ChAT and
TH expression are controlled through separate
transcriptional promoter pathways, compris-
ing cAMP-dependent processes (adenylyl
cyclase, protein kinase A, CREB, AP-1) as well
as trophic factors such as brain derived neuro-
trophic factor, ciliary neurotrophic factor,
repressor element-1 silencing transcription fac-
tor/neuron restrictive silencer factor, and bone
morphogenetic protein-9 (Lewis-Tufﬁn et al.
2004; Lopez-Coviella et al. 2000; Shimojo
and Hersh 2004; Slonimsky et al. 2003).
There is abundant evidence for CPF’s target-
ing of the cAMP signaling cascade and its
associated downstream transcriptional ele-
ments (Casida and Quistad 2004; Crumpton
et al. 2000; Meyer et al. 2003; Schuh et al.
2002; Song et al. 1997), and our results sug-
gest the need to explore the impact on other
transcriptional factors speciﬁc to neuronal dif-
ferentiation into the cholinergic and cate-
cholaminergic phenotypes; it is quite likely
that the targeting of ChAT versus TH results
from activation or suppression of some of
these factors or their downstream effectors at
speciﬁc developmental stages.
The viability and differentiation of PC12
cells require the inclusion of fetal calf and horse
serum and their associated proteins (Crumpton
et al. 2000; Das and Barone 1999; Fujita et al.
1989; Madhok and Sharp 1992; Qiao et al.
2001, 2005; Song et al. 1998; Teng and
Greene 1994). Organophosphates, including
CPF, are highly bound to albumin, thereby
lowering the bioeffective CPF concentration
both in vivo and in culture (Braeckman et al.
1983; Qiao et al. 2001). Earlier, we showed
that serum proteins protect PC12 cells from
the adverse effects of CPF (Qiao et al. 2001),
and accordingly, their inclusion in the present
study means that the suppressed emergence of
the cholinergic phenotype is exerted at CPF
concentrations well below those actually added
to the cultures. The same factors are likely to
be important for CPF effects on brain develop-
ment in vivo. The fetus and neonate have
lower concentrations of serum albumin than
does the adult, so the bioeffective concentra-
tion of CPF is higher than at the correspond-
ing level in the mother (Thom et al. 1967;
Yaffe and Stern 1976). Furthermore, because
albumin concentrations correlate with somatic
growth (Thom et al. 1967), low-birth-weight
infants may be especially susceptible to the
effects of CPF. The “Barker Hypothesis”
relates low birth weight to the emergence of
cardiovascular and metabolic diseases later in
life (Barker 2003), and thus our results suggest
that this relationship may equally apply to
adverse neurodevelopmental consequences
after exposure to environmental toxicants.
One ﬁnal question is whether these effects
are specific to CPF or rather are shared by
other organophosphate insecticides or by non-
organophosphate cholinesterase inhibitors
such as carbamates. Like CPF, diazinon inhibits
DNA synthesis in undifferentiated PC12 cells,
whereas physostigmine, a carbamate, is less
effective (Qiao et al. 2001). Despite that, in
cells undergoing NGF-induced differentiation,
we found greater cell loss with physostigmine
(35% reduction in DNA) than with CPF (20%
reduction), implying that the carbamate deriva-
tive is more generally deleterious in long-term
exposures of differentiating cells. In part, this
likely reﬂects the fact that physostigmine does
not bind as strongly to serum proteins
(Whelpton and Hurst 1990), so its effective
concentration in the culture system may be
considerably higher than that of CPF. Over and
above effects on cell number, the fact that
physostigmine shares the ability to inhibit dif-
ferentiation into the cholinergic phenotype
strongly suggests a common contributing fac-
tor. The ﬁrst likely explanation is cholinesterase
inhibition. Indeed, a transition occurs in vivo
for the effects of CPF on cell acquisition and
differentiation, where actions are initially inde-
pendent of cholinergic hyperstimulation but
become increasingly cholinesterase-related as
differentiation proceeds (Slotkin 1999, 2004).
However, we also detected effects of CPF on
ChAT at low concentrations that did not
impair cell acquisition and below the threshold
for cholinesterase inhibition; furthermore,
cholinesterase knockout mice show normal
development of cholinergic projections, includ-
ing unchanged expression of ChAT (Volpicelli-
Daley et al. 2003). It is therefore possible that
organophosphates and carbamates share addi-
tional mechanisms other than cholinesterase
inhibition that nevertheless contribute to
developmental neurotoxicity targeted to the
cholinergic phenotype. These complex relation-
ships also are apparent in other test systems. In
aggregating cultures of primary neurons and
glia, CPF inhibits the emergence of the cholin-
ergic phenotype much more than does
parathion, despite the fact that the latter is
more systemically toxic and more potent
toward cholinesterase inhibition, and physo-
stigmine is less effective (Monnet-Tschudi et al.
2000; Zurich et al. 2004). Again, our ﬁndings
are entirely compatible: although physo-
stigmine reduced ChAT:DNA 20%, CPF pro-
duced a much greater effect (40% deficit)
without a comparable degree of cell loss.
In conclusion, CPF exerts stage-specific
effects on neuronal development, reducing
DNA synthesis in the undifferentiated state,
impairing emergence of the cholinergic pheno-
type at the start of differentiation, and promot-
ing expression of the catecholaminergic
phenotype in both undifferentiated and differ-
entiated cells. Because similar effects are seen
in vivo after fetal or neonatal CPF exposures at
levels below the threshold for systemic effects or
even for cholinesterase inhibition (Barone et al.
2000; Casida and Quistad 2004; Gupta 2004;
Pope 1999; Slotkin 1999, 2004; Slotkin et al.
2001), it is likely that CPF has a direct effect
on neuronal differentiation, speciﬁcally com-
promising the development of the cholinergic
phenotype. In turn, these alterations may
relate mechanistically to deﬁcient cholinergic
synaptic function and later-developing neu-
robehavioral deﬁcits (Barone et al. 2000; Pope
1999; Rice and Barone 2000; Slotkin 2004).
Neurodevelopmental effects of chlorpyrifos
Environmental Health Perspectives • VOLUME 114 | NUMBER 5 | May 2006 671Finally, given the relative facility with which
multiple end points of cell acquisition, cyto-
toxicity, and phenotypic differentiation can be
evaluated in the PC12 system, we suggest that
this model can be especially useful for the
rapid screening of neurodevelopmental out-
comes of related or disparate environmental
neurotoxicants.
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